SEAL ROCK THERAPEUTICS, INC.
SRT-015, a selective ASK1 kinase inhibitor molecule for treating severe acute alcoholic hepatitis
- Sector
- Biotech
- Headquarters
- Seattle, WA
- Latest Form D
- $2.5M, Feb 2022
- Total capital
- $3.2M
- Federal grants
- $705K
- 2 awards · 2022–2025
- Rank in peer group#99 of 502
- Private capital raised
- $2.5M
- 1 Form D · last Feb 2022
- 56 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 18 pending · first 2018
- Rank in peer group#41 of 502
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Targeting ASK1 as a novel therapy to treat biliary atresia$347K
- Federal grantHealth and Human S · Phase I · A novel therapy for acute alcoholic hepatitis$358K
- Private capital raisedForm D · SEC · 1st filing$2.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grants#99 · top 20%
- Granted patents#41 · top 8%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Neil McDonnellResearcherExecutive Officer, Director, PromoterLinked by $705K in grants as PI
- Artur PlonowskiExecutive Officer, Director, PromoterNamed in SEC Form D filings
- Keith WycoffDirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 20- PendingMethod Of Treating Organ Diseases Or Disorders With ASK1 InhibitorsUSPTOApplication 18996525
- PendingASK1 Inhibitor Compounds And Uses ThereofUSPTOApplication 18897798
- GrantedASK1 Inhibitor Compounds And Uses ThereofUSPTOUS 11,434,249
Show all 20 patent records
- Method Of Treating Organ Diseases Or Disorders With ASK1 InhibitorsJan 22, 2026 · Application 18996525Pending
- ASK1 Inhibitor Compounds And Uses ThereofOct 2, 2025 · Application 18897798Pending
- ASK1 Inhibitor Compounds And Uses ThereofSep 6, 2022 · US 11,434,249Granted
- Methods Of Treating Neurodegenerative DiseasesJul 15, 2021 · Application 17271883Pending
- ASK1 Inhibitor Compounds And Uses ThereofMar 25, 2021 · Application 16499075Pending
- ASK1 Inhibitor Compounds And Uses ThereofDec 11, 2018 · US 10,150,755Granted
- Method Of Treating Organ Diseases Or Disorders With ASK1 InhibitorsApplication 63368961Pending
- Methods Of Treating Neurodegenerative DiseasesApplication PCTUS2019048388Pending
- ASK1 Inhibitor Compounds And Uses ThereofApplication PCTUS2018068187Pending
- ASK1 Inhibitor Compounds And Uses ThereofApplication 62783746Pending
- Methods Of Treating Neurodegenerative DiseasesApplication 62724574Pending
- ASK1 Inhibitor Compounds And Uses ThereofApplication PCTUS2018026134Pending
- ASK1 Inhibitor Compounds And Uses ThereofApplication 62612990Pending
- Method Of Treating Liver Diseases Or Disorders With ASK1 InhibitorsApplication PCTUS2025050922Pending
- ASK1 Inhibitor Compounds And Uses ThereofApplication 62482085Pending
- Method Of Treating Liver Diseases Or Disorders With ASK1 InhibitorsApplication 63708139Pending
- ASK1 Inhibitor Compounds And Uses ThereofApplication 18405470Pending
- Method Of Treating Organ Diseases Or Disorders With ASK1 InhibitorsApplication PCTUS2023070517Pending
- ASK1 Inhibitor Compounds And Uses ThereofApplication 18319914Pending
- ASK1 Inhibitor Compounds And Uses ThereofApplication 17936672Pending
Related companies, and why
- Sentia Medical Sciences, Inc.Similar federal contract value in Biotech · null in contracts
- ILUMINOS THERAPEUTICS LLCSimilar federal contract value in Biotech · null in contracts
- NeuroCycle Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- LYCHEE BIOSCIENCE LLCSimilar federal contract value in Biotech · null in contracts
- FORWARD DEFENSE, LLCSimilar federal contract value in Biotech · null in contracts
- IMMUNOQ THERAPEUTICS INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .